Table 1 Demographic, basal clinical and laboratory parameters

Male gender

44 (50%)

Age (years)

29 (12–36)

Subjects with comorbidities

28 (31.82%)

 Hypertension

8 (13.63%)

 Osteoporosis

12 (13.63%)

 HBV

4 (4.54%)

 Drug users

4 (4.54%)

Splenectomy

88 (100%)

Iron chelation agent

 Deferiprone

28 (31.82)

 Deferasirox

60 (68.18)

Hemoglobin (g/dl)

8.25 (7.3–9)

Platelet count (×10⁹/L)

543 (430–632)

WBCs (× 10⁹/L)

27.3 (18.3–50)

AST (IU/L)

71.50 (47–82.30)

ALT (IU/L)

54.45 (28–74)

S. bilirubin (mg/dl)

2.9 (2.5–4)

Direct bilirubin (mg/dl)

0.6 (0.5–0.98)

Albumin (g/dl)

4 (3.8–4.8)

INR

1.2 (1.1–1.3)

S. creatinine (mg/dl)

0.65 (0.6–0.8)

Ferritin (ng/mL)

2500 (1800–4000)

PCR HCV RNA (IU/ml)

941757 (187771–1400000)

FIB-4 score

0.52 (0.47–0.73)